----
Current ValuationThe current P/E ratio is -14.89, within the reasonable range, cheaper than 79.28% of the time in the past 3 years, and the industry ranks 56/78, the industry Median -5.11.
-14.89xP/E
HK$19.31Stock price
HK$-1.30Earnings per share
-14.89xP/E
Stock priceHK$19.31Earnings per shareHK$-1.30
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -10.87x
- Typical range
- -15.05x–-6.62x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0155310465620
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -88.68x | 77.35% | HK$98.75B |
09688HKZAI LAB | -14.89x | 378.99% | HK$21.97B |
01877HKJUNSHI BIO | -38.47x | 85.33% | HK$17.80B |
09606HKDUALITYBIO-B | -9.90x | 85.58% | HK$16.40B |
07666HKMETIS TECHBIO-P | -38.50x | 96.70% | HK$15.67B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
01952HKEVEREST MED | -182.71x | 324.61% | HK$11.34B |
06855HKASCENTAGE | -6.63x | 18.68% | HK$11.20B |
02595HKGENFLEET-B | -6.97x | 78.32% | HK$10.57B |
06938HKRIBOLIFE-B | -47.36x | 29.88% | HK$9.25B |
02493HKMABWELL-B | -8.42x | -- | HK$9.11B |
09887HKLEADS BIOLABS-B | -29.52x | 8.67% | HK$9.07B |
02616HKCSTONE PHARMA-B | -16.54x | 1.72% | HK$7.98B |
02335HKMICOT PHARMA-B | -17.31x | 37.50% | HK$7.27B |
01672HKASCLETIS-B | -10.57x | 78.59% | HK$7.20B |
09966HKALPHAMAB-B | -34.25x | -- | HK$6.94B |
02171HKCARSGEN-B | -67.02x | 51.12% | HK$6.88B |
01779HKLONGBIO-B | -27.38x | -- | HK$6.82B |
02256HKABBISKO-B | -10.27x | 300.95% | HK$5.52B |
06872HKTENNOR THERAP-B | -33.54x | -- | HK$5.38B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
